This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Summary: Defining Remission in Patients Treated With Antidepressants

Michael E. Thase, MD

Published: August 1, 1999

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

These review articles reflect the presentations that were given at a conference held in Dallas, Texas, in January 1999. Both the conference and this series sought to establish the criteria necessary for measuring remission, or wellness, in patients with depression, anxiety, or comorbid depression with anxiety and to evaluate the pharmacotherapeutic options best suited to meet these new standards.

Today, depression and anxiety are viewed as two ends of a continuum, with a significant degree of comorbidity occurring between them1; two thirds of patients with depression have experienced a previous anxiety disorder. The highest rate of anxiety comorbid with depression occurs with generalized anxiety disorder (GAD).

Volume: 2

Quick Links: Depression (MDD)


Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...